Industry Insights - The U.S. government, under President Trump, is reportedly discussing measures to restrict Chinese pharmaceuticals, including drafting an executive order aimed at limiting the entry of innovative Chinese drugs into the U.S. market [1] - Goldman Sachs' latest report indicates that this situation could introduce "headline risk" to the Chinese biotech and pharmaceutical sector, potentially increasing stock price volatility [1] Company Specifics - Shares of 基石药业-B (2616.HK) experienced a significant drop of 22.88%, reaching a low of 9.1 HKD, marking the lowest point since August 25 [1] - Recent disclosures from the Hong Kong Stock Exchange reveal that non-executive director 胡正国 sold 223,000 shares at an average price of 12.007 HKD per share on September 5, totaling approximately 2.678 million HKD. Following this transaction, his ownership percentage decreased from 0.18% to 0.17% [1]
港股异动丨基石药业一度重挫约23% 消息称美国拟加强审查中国创新药+股东减持